Breast Cancer

, Volume 21, Issue 4, pp 387–393 | Cite as

Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy

  • Hyun Jung Lee
  • Dae Young Kim
  • Bhumsuk Keam
  • Jeong Hoon Lee
  • Sae-Won Han
  • Do-Youn Oh
  • Jung Hwan Yoon
  • Tae-You Kim
  • Yu Jung Kim
  • Keun Wook Lee
  • Jin-Wook Kim
  • Sook-Hyang Jeong
  • Jong Seok Lee
  • Jee Hyun Kim
  • Seock-Ah Im
Original Article
First Online:
Received:
Accepted:

Abstract

Background

This study aimed to assess the efficacy of lamivudine prophylaxis on hepatic complications in HBsAg-positive patients with breast cancer undergoing adjuvant chemotherapy and to describe the temporal trend in HBV surveillance and prophylaxis during the last decade.

Methods

Patients with stage I–III curatively resected invasive breast cancer who received adjuvant and/or neoadjuvant chemotherapy between 2000 and 2009 were eligible for this study. Patients with positive HBsAg and normal liver function were enrolled. Hepatotoxicity, defined as alanine aminotransferase (ALT) ≥100 IU/ml, and HBV reactivation were compared according to lamivudine prophylaxis. Annual trends in HBV surveillance and use of lamivudine prophylaxis were also reviewed.

Results

One hundred sixty-five HBsAg-positive patients with breast cancer were enrolled. After the year 2004, surveillance of HBV infection status and use of lamivudine prophylaxis increased significantly (2.5 vs. 57.6 %, P < 0.001). Seventy-three (44.2 %) patients received lamivudine prophylaxis and 92 (55.8 %) patients did not. The incidence of hepatotoxicity was significantly lower in the group receiving prophylaxis (2.7 vs. 14.1 %, P = 0.011) with fewer premature terminations of planned adjuvant chemotherapy (0 vs. 10.9 %, P = 0.004) in the prophylaxis group. Among the patients for whom the baseline HBV DNA titer was available, the HBV reactivation rate was lower, albeit not significantly, in the prophylaxis group (0 %) compared with the no prophylaxis group (20 %) (P = 0.104). Lamivudine-withdrawal hepatitis was not detected; however, one case of breakthrough HBV reactivation during lamivudine treatment was observed in this study.

Conclusions

Over the past decade, there has been an increase in the awareness of HBV reactivation and in the use of lamivudine during cytotoxic chemotherapy. Lamivudine prophylaxis reduced hepatic complications during adjuvant chemotherapy in patients with breast cancer. Lamivudine prophylaxis should be considered in HBsAg-positive patients with breast cancer who are candidates for adjuvant chemotherapy.

Keywords

Hepatitis B virus Reactivation Breast cancer Lamivudine 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A040151).

References

  1. 1.
    Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.PubMedGoogle Scholar
  2. 2.
    Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997;8(suppl 1):S107.CrossRefGoogle Scholar
  3. 3.
    Liang R, Lau GKK, Kwong Y. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17(1):394.PubMedGoogle Scholar
  4. 4.
    Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299–307.PubMedCrossRefGoogle Scholar
  5. 5.
    Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90(7):1306–11.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Cheng AL. Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin’s lymphoma. Blood. 1996;87(3):1202.PubMedGoogle Scholar
  7. 7.
    NCI. Cancer incidence in 2008. Available from: http://www.cancer.go.kr/cms/statics/incidence/index.html (2010).
  8. 8.
    Jeong S, Yim HW, Bae SH, Lee W. Changes of hepatitis B surface antigen seroprevalence in Korea, 1998–2005. Korean J Epidemiol. 2008;30(1):119–27.CrossRefGoogle Scholar
  9. 9.
    Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148(7):519–28.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2006;24(7):1003–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Yeo W, Ho WM, Hui P, Chan PK, Lam KC, Lee JJ, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2004;88(3):209–15.PubMedCrossRefGoogle Scholar
  12. 12.
    Dai MS, Wu PF, Shyu RY, Lu JJ, Chao TY. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004;24(6):540–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Yun J, Kim K, Kang E, Gwak G, Choi M, Lee J, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104(4):559–63.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Lee KS, Kim DJ. Management of chronic hepatitis B. Korean J Hepatol. 2007;13(4):447–88.Google Scholar
  15. 15.
    Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat. 2008;15(2):89–102.PubMedGoogle Scholar
  16. 16.
    Gauthier J, Bourne EJ, Lutz MW, Crowther LM, Dienstag JL, Brown NA, et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis. 1999;180(6):1757–62.PubMedCrossRefGoogle Scholar
  17. 17.
    Keam B, Lee JH, Im SA, Yoon JH. Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy. J Natl Compr Canc Netw. 2011;9(5):465–77.PubMedGoogle Scholar
  18. 18.
    Pelizzari AM, Motta M, Cariani E, Turconi P, Borlenghi E, Rossi G. Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies. Hematol J. 2004;5(4):325–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee YC, Young KC, Su WC, Tsao CJ, Chen TY. Emergence of YMDD mutant hepatitis B virus after allogeneic stem cell transplantation from a HBsAG-positive donor during lamivudine prophylaxis. Haematologica. 2004;89(4):ECR09.Google Scholar
  20. 20.
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682–95.PubMedCrossRefGoogle Scholar
  21. 21.
    Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125(6):1742–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2(2):152–62.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2012

Authors and Affiliations

  • Hyun Jung Lee
    • 1
  • Dae Young Kim
    • 2
  • Bhumsuk Keam
    • 1
  • Jeong Hoon Lee
    • 3
  • Sae-Won Han
    • 1
  • Do-Youn Oh
    • 1
  • Jung Hwan Yoon
    • 3
  • Tae-You Kim
    • 1
  • Yu Jung Kim
    • 4
  • Keun Wook Lee
    • 4
  • Jin-Wook Kim
    • 5
  • Sook-Hyang Jeong
    • 5
  • Jong Seok Lee
    • 4
  • Jee Hyun Kim
    • 4
  • Seock-Ah Im
    • 1
  1. 1.Division of Hematology-Oncology, Department of Internal MedicineSeoul National University Hospital, Seoul National University College of MedicineSeoulKorea
  2. 2.Department of Hematology, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulKorea
  3. 3.Division of Gastroenterology-Hepatology, Department of Internal MedicineSeoul National University Hospital, Seoul National University College of MedicineSeoulKorea
  4. 4.Division of Hematology-Oncology, Department of Internal MedicineSeoul National University Bundang Hospital, Seoul National University College of MedicineSeongnam-siKorea
  5. 5.Division of Gastroenterology-Hepatology, Department of Internal MedicineSeoul National University Bundang Hospital, Seoul National University College of MedicineSeongnam-siKorea

Personalised recommendations